A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma

被引：5
|
作者：
Dunne, Richard Francis
Ullman, Nicholas A.
Belt, Brian A.
Ruffolo, Luis I.
Burchard, Paul
Hezel, Aram F.
Zittel, Jason
Wang, Wenjia
Ramsdale, Erika E.
Kaul, Vivek
Zebala, John
Linehan, David
机构：
[1] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA
[2] Univ Rochester, Med Ctr, Dept Surg, Rochester, NY 14642 USA
[3] Univ Rochester, Med Ctr, Dept Med, Div Gastroenterol, Rochester, NY 14642 USA
[4] Syntrix Pharmaceut, Auburn, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS631
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Phase I/ II Study of Concurrent Chemoradiotherapy With Gemcitabine and S-1 for Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, T.
    Arimoto, N.
    Ashida, R.
    Takakura, R.
    Nakamura, S.
    Nishiyama, K.
    Tanaka, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S451 - S451
  • [42] Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study
    Wang, Shanshan
    Wang, Yunchao
    Zhu, Chengpei
    Liu, Kai
    Chao, Jiashuo
    Zhang, Nan
    Piao, Mingjian
    Yang, Xu
    Zhang, Longhao
    Long, Junyu
    Xun, Ziyu
    Zhang, Ting
    Sang, Xinting
    Yang, Xiaobo
    Zhao, Haitao
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (08) : 4608 - 4616
  • [43] A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo Espanol Multidisciplinario en Cancer Digestivo (GEMCAD) Study
    Aparicio, Jorge
    Garcia-Mora, Carmen
    Martin, Marta
    Lourdes Petriz, Ma
    Feliu, Jaime
    Elena Sanchez-Santos, Ma
    Ramon Ayuso, Juan
    Fuster, David
    Conill, Carlos
    Maurel, Joan
    PLOS ONE, 2014, 9 (01):
  • [44] Hepatic arterial infusion chemotherapy in combination with PD-1 inhibitor as conversion therapy in locally advanced, potentially resectable hepatocellular carcinoma: A phase II study
    Xu, Li
    Zhang, Yaojun
    Chen, Minshan
    Wang, Xiaohui
    Hou, Jingyu
    Zhou, Zhongguo
    JOURNAL OF HEPATOLOGY, 2021, 75 : S247 - S247
  • [45] A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA).
    Tebbutt, Niall C.
    Kotasek, Dusan
    Borad, Mitesh J.
    Borazanci, Erkut Hasan
    Smith, Sheri Lynn
    Shah, Ajit K.
    Walker, Michael J.
    Cullen, Michael T.
    Gagnon, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study
    Yang, Jianliang
    Dong, Lihou
    Yang, Sheng
    Han, Xiaohong
    Han, Ying
    Jiang, Shiyu
    Yao, Jiarui
    Zhang, Zhishang
    Zhang, Shuxiang
    Liu, Peng
    Qin, Yan
    Wu, Hai
    Feng, Hui
    Yao, Sheng
    Sun, Yan
    Song, Haifeng
    Shi, Yuankai
    EUROPEAN JOURNAL OF CANCER, 2020, 130 : 182 - 192
  • [47] A phase Ib/II clinical trial of tolerability, safety and efficacy of regorafenib in combination with toripalimab (a PD-1 antibody) in patients with relapsed or metastatic colorectal cancer
    Wang, F.
    He, M-M.
    Yao, Y-C.
    Wang, Z-Q.
    Jin, Y.
    Wang, F-H.
    Qiu, M-Z.
    Lv, Z-D.
    Wang, S.
    Luo, H-Y.
    Li, Y-H.
    Zhang, D-S.
    Xu, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S425 - S425
  • [48] Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
    Akahori, Takahiro
    Sho, Masayuki
    Yanagimoto, Hiroaki
    Satoi, Sohei
    Nagai, Minako
    Nishiwada, Satoshi
    Nakagawa, Kenji
    Nakamura, Kota
    Yamamoto, Tomohisa
    Hirooka, Satoshi
    Yamaki, So
    Ikeda, Naoya
    ONCOLOGIST, 2019, 24 (06): : 749 - E224
  • [49] DEnosumab plus PD-1 Inhibitor for MAINtenance Therapy of Advanced KRAS-Mutant NSCLC - A Prospective, Single-Arm, Phase II Study (DEMAIN)
    Li, H.
    Xu, H. -Y.
    Duan, J. -C.
    Wang, Z. -J.
    Zhong, J.
    Cui, Y. -Y.
    Fang, Q.
    Lei, S-Y.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S317 - S317
  • [50] The Phase 1 Study of Concurrent Chemoradiation Therapy With Gemcitabine and Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Adenocarcinoma Patients
    Ioka, T.
    Katayama, K.
    Takada, R.
    Fukutake, N.
    Ohkawa, K.
    Akita, H.
    Takahashi, H.
    Konishi, K.
    Teshima, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S205 - S205
12345